HBM Holdings (FRA:6XY) Gross-Profit-to-Asset % : 10.35% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. HBM Holdings's annualized Gross Profit for the quarter that ended in Dec. 2024 was €21.20 Mil. HBM Holdings's average Total Assets over the quarter that ended in Dec. 2024 was €204.72 Mil. Therefore, HBM Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 10.35%.

HBM Holdings Gross-Profit-to-Asset % Historical Data

The historical data trend for HBM Holdings's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Gross-Profit-to-Asset % Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

5.88

1.30

16.31

37.42

15.48

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial								10.35	35.56	41.01	20.23	10.35

Competitive Comparison of HBM Holdings's Gross-Profit-to-Asset %

For the Biotechnology subindustry, HBM Holdings's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HBM Holdings's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where HBM Holdings's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

HBM Holdings Gross-Profit-to-Asset % Calculation

HBM Holdings's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	32.101	/	( (209.516	+	205.338)	/ 2 )
	=	32.101	/	207.427
	=	15.48 %

HBM Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	21.198	/	( (204.107	+	205.338)	/ 2 )
	=	21.198	/	204.7225
	=	10.35 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

HBM Holdings Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (FRA:6XY) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

HBMHF:USA 02142:Hong Kong

Address

218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

HBM Holdings Headlines

No Headlines